A Phase 3 interventional study of DZP and Placebo in Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL. Completed at 177 sites in 25 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-05-04.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 3, and was the 17th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
Candid Therapeutics · Sites in China
Ages 18–75
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 20 more countries
Ages 16+
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 21 more countries
Ages 16+
UCB Biopharma SRL
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 9
First in 2005; this study’s year is marked. 1 started in 2020.
This study's enrollment of 321 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study participants who have moderate to severe disease activity due to either persisting active SLE or due to an acute worsening of SLE in the scope of frequent flaring/relapsing-remitting systemic lupus erythematosus (SLE) despite stable standard of care (SOC) medication defined as:
a. Diagnosed with SLE at least 24 weeks before the Screening Visit (Visit 1) study entry by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (in central laboratory at Screening) ii) Either complement C3 \< lower limit of normal (LLN) OR complement C4 \<LLN OR elevated erythrocyte-bound complement C4d (where available) as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:
d. Moderately to severely active defined as
SLEDAI-2K without labs ≥4 at Baseline Visit
e. Receiving the following SOC medication at stable dose:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive dapriolizumab pegol througout the Treatment Period.
Drug: DZP
Subjects will receive placebo througout the Treatment Period.
Other: Placebo
Subjects will receive dapirolizumab pegol at prespecified time-points.
Also known as: CDP7657
Subjects will receive placebo at prespecified time-points.
Also known as: PBO
Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48
Study participants were considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following were fulfilled: * British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and less than or equal to \[≤\] 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as \[≤\] 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS).
Time frame: Week 48
Percentage of Participants With Achievement of BICLA Response at Week 24
Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.
Time frame: Week 24
Percentage of Participants With Achievement of BICLA Response at Week 12
Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.
Time frame: Week 12
Percentage of Participants With Achievement of Prevention of Severe British Isles Lupus Assessment Group (BILAG) Flares (Severe BILAG Flare-free) Through Week 48
A severe BILAG flare was defined as a british isles lupus assessment group disease activity index 2004 (BILAG 2004) Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A were according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy.
Time frame: During Treatment Period up to Week 48
Percentage of Participants With Achievement of Lupus Low Disease Activity State (LLDAS) in ≥50% of Post-Baseline Visits Through Week 48
The LLDAS includes domains that capture the absence of organ-threatening disease activity and harmful treatment burden. The LLDAS is defined as: * SLEDAI-2K score was ≤4 with no activity in major organ systems. * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at the previous visit. * PGA ≤ 33 mm. * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤ 7.5 mg per day. * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol, defined as no increase in dose in the past 12 weeks and no dose higher than allowed as per protocol.
Time frame: During Treatment Period up to Week 48
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at Week 48
The SLEDAI-2K is a global index which includes 24 clinical and laboratory variables such as antibodies, renal, and hematological components measured 30 days before, and at the timepoint of assessment. The variables were weighted by the type of manifestation, but not by severity or dynamic of the individual item. The SLEDAI-2K includes scoring for antibodies (anti-dsDNA positive or negative) and low complement, as well as some renal and hematologic parameters. The total score falls between 0 and 105, with higher scores representing increased disease activity. Mixed effects models for repeated measurements (MMRM).
Time frame: From Baseline (Day 1) to Week 48
Percentage of Participants With Achievement of BILAG Improvement Without Worsening at Week 48
The BILAG improvement without worsening defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B Score. Here, score A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy; score B ("Beware"): Moderately active disease (requires low dose or local immunosuppressant therapy or symptomatic therapy; score C ("Contentment"): Mild stable disease (no indication for changes in treatment); score D ("Discount"): Inactive now but previously active.
Time frame: Week 48
Change From Baseline in Physician's Global Assessment (PGA) at Week 48
The PGA is a measure of systemic lupus erythematosus (SLE) signs and symptoms by the physician using a visual analog scale of 0 to 100mm, Where 0 indicate "very good", asymptomatic, and no limitation of normal activity and 100 indicate "severe disease".
Time frame: From Baseline (Day 1) to Week 48
Percentage of Participants With Achievement of Systemic Lupus Erythematosus Responder Index Response - 4 (SRI-4) Response at Week 48
The SRI-4 define responders as meeting all of the following criteria: * Reduction in SLEDAI-2K score of ≥ 4. * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease; Grade C ("Contentment"): Mild stable disease; Grade D ("Discount"): Inactive now but previously active; Grade E ("Excluded"): Never affected. * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline. * No worsening in the PGA compared to study entry defined as ≤ 10 mm increase on a 100 mm visual analog scale, equivalent to less than a 10 mm increase in the PGA compared to study entry score.
Time frame: Week 48
Percentage of Participants With Achievement of Prevention of Moderate/Severe BILAG Flares (Moderate/Severe BILAG Flare-free) Through Week 48
Achievement of prevention of moderate/severe BILAG flares through Week 48 was defined as the percentage of participants with no moderate or severe flare through Week 48. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. A moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG- 2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.
Time frame: During Treatment Period up to Week 48
Time to Severe BILAG Flare Through Week 48
Time to severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease.
Time frame: During Treatment Period up to Week 48
Time to Moderate/Severe BILAG Flare Through Week 48
Time to moderate/severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. Moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and are qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.
Time frame: During Treatment Period up to Week 48
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; and Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest During the Study
An adverse event of special interest (AESIs) is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a product/compound.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Percentage of Participants With Treatment-emergent Adverse Events of Special Monitoring During the Study
An AE of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
The study started to enroll participants in August 2020 and concluded in June 2024.
| Milestone | PBO+SOC | DZP+SOC |
|---|---|---|
| Started | 108 | 213 |
| Completed | 91 | 192 |
| Not completed | 17 | 21 |
| Withdrew: Lack of efficacy | 4 | 4 |
| Withdrew: Consent withdrawal by study participant | 9 | 7 |
| Withdrew: Patient has a renal flare | 1 | 0 |
| Withdrew: Sle worsening | 0 | 1 |
| Withdrew: Subject decision due to personal reason | 0 | 1 |
| Withdrew: Pi closed site - subject early withdrawal | 0 | 1 |
| Withdrew: Subject withdrew due to personal reason | 0 | 1 |
| Withdrew: Subject moved to another state | 0 | 1 |
| Withdrew: Adverse event, serious fatal | 0 | 1 |
| Withdrew: Adverse event, non-fatal | 3 | 4 |
Study participants were considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following were fulfilled: * British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and less than or equal to \[≤\] 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as \[≤\] 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS).
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48 | 34.6 | 49.5 |
Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of BICLA Response at Week 24 | 38.3 | 46.6 |
Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of BICLA Response at Week 12 | 29.0 | 39.9 |
A severe BILAG flare was defined as a british isles lupus assessment group disease activity index 2004 (BILAG 2004) Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A were according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of Prevention of Severe British Isles Lupus Assessment Group (BILAG) Flares (Severe BILAG Flare-free) Through Week 48 | 76.6 | 88.4 |
The LLDAS includes domains that capture the absence of organ-threatening disease activity and harmful treatment burden. The LLDAS is defined as: * SLEDAI-2K score was ≤4 with no activity in major organ systems. * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at the previous visit. * PGA ≤ 33 mm. * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤ 7.5 mg per day. * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol, defined as no increase in dose in the past 12 weeks and no dose higher than allowed as per protocol.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of Lupus Low Disease Activity State (LLDAS) in ≥50% of Post-Baseline Visits Through Week 48 | 15.9 | 23.6 |
The SLEDAI-2K is a global index which includes 24 clinical and laboratory variables such as antibodies, renal, and hematological components measured 30 days before, and at the timepoint of assessment. The variables were weighted by the type of manifestation, but not by severity or dynamic of the individual item. The SLEDAI-2K includes scoring for antibodies (anti-dsDNA positive or negative) and low complement, as well as some renal and hematologic parameters. The total score falls between 0 and 105, with higher scores representing increased disease activity. Mixed effects models for repeated measurements (MMRM).
| score on a scale | PBO+SOC | DZP+SOC |
|---|---|---|
| Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at Week 48 | -4.2 ± 0.39 | -6.1 ± 0.26 |
The BILAG improvement without worsening defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B Score. Here, score A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy; score B ("Beware"): Moderately active disease (requires low dose or local immunosuppressant therapy or symptomatic therapy; score C ("Contentment"): Mild stable disease (no indication for changes in treatment); score D ("Discount"): Inactive now but previously active.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of BILAG Improvement Without Worsening at Week 48 | 34.6 | 49.5 |
The PGA is a measure of systemic lupus erythematosus (SLE) signs and symptoms by the physician using a visual analog scale of 0 to 100mm, Where 0 indicate "very good", asymptomatic, and no limitation of normal activity and 100 indicate "severe disease".
| score on a scale | PBO+SOC | DZP+SOC |
|---|---|---|
| Change From Baseline in Physician's Global Assessment (PGA) at Week 48 | -33.4 ± 1.99 | -39.6 ± 1.36 |
The SRI-4 define responders as meeting all of the following criteria: * Reduction in SLEDAI-2K score of ≥ 4. * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease; Grade C ("Contentment"): Mild stable disease; Grade D ("Discount"): Inactive now but previously active; Grade E ("Excluded"): Never affected. * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline. * No worsening in the PGA compared to study entry defined as ≤ 10 mm increase on a 100 mm visual analog scale, equivalent to less than a 10 mm increase in the PGA compared to study entry score.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of Systemic Lupus Erythematosus Responder Index Response - 4 (SRI-4) Response at Week 48 | 41.1 | 60.1 |
Achievement of prevention of moderate/severe BILAG flares through Week 48 was defined as the percentage of participants with no moderate or severe flare through Week 48. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. A moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG- 2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Achievement of Prevention of Moderate/Severe BILAG Flares (Moderate/Severe BILAG Flare-free) Through Week 48 | 63.0 | 78.6 |
Time to severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease.
| weeks | PBO+SOC | DZP+SOC |
|---|---|---|
| Time to Severe BILAG Flare Through Week 48 | NA (NA to NA) | NA (NA to NA) |
Time to moderate/severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. Moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and are qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.
| weeks | PBO+SOC | DZP+SOC |
|---|---|---|
| Time to Moderate/Severe BILAG Flare Through Week 48 | NA (36.1 to NA) | NA (NA to NA) |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 75.0 | 82.6 |
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; and Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study | 14.8 | 9.9 |
An adverse event of special interest (AESIs) is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a product/compound.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events of Special Interest During the Study | 0.9 | 0 |
An AE of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.
| percentage of participants | PBO+SOC | DZP+SOC |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events of Special Monitoring During the Study | 24.1 | 36.6 |
Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 54). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PBO+SOC | 0/108 (0%) | 16/108 (14.8%) | 47/108 (43.5%) |
| DZP+SOC | 1/213 (0.5%) | 21/213 (9.9%) | 109/213 (51.2%) |
| Event | PBO+SOC | DZP+SOC |
|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/108 | 3/213 |
| Ophthalmic herpes zosterInfections and infestations | 0/108 | 2/213 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/108 | 2/213 |
| Lupus enteritisGastrointestinal disorders | 1/108 | 0/213 |
| Chest painGeneral disorders | 1/108 | 0/213 |
| AppendicitisInfections and infestations | 1/108 | 0/213 |
| DiverticulitisInfections and infestations | 1/108 | 0/213 |
| Diverticulitis intestinal perforatedInfections and infestations | 1/108 | 0/213 |
| Bacterial colitisInfections and infestations | 1/108 | 0/213 |
| Herpes zosterInfections and infestations | 1/108 | 0/213 |
| Event | PBO+SOC | DZP+SOC |
|---|---|---|
| COVID-19Infections and infestations | 17/108 | 44/213 |
| Urinary tract infectionInfections and infestations | 9/108 | 28/213 |
| NasopharyngitisInfections and infestations | 13/108 | 18/213 |
| Upper respiratory tract infectionInfections and infestations | 8/108 | 20/213 |
| DiarrhoeaGastrointestinal disorders | 10/108 | 15/213 |
| HeadacheNervous system disorders | 7/108 | 15/213 |
| NauseaGastrointestinal disorders | 6/108 | 9/213 |
| Herpes zosterInfections and infestations | 6/108 | 4/213 |
| Oral herpesInfections and infestations | 6/108 | 4/213 |
| BronchitisInfections and infestations | 5/108 | 11/213 |
Baseline Characteristics refer to the Safety Set (SS) which consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.
| Age, Continuous(Years) | PBO+SOC | DZP+SOC | Total |
|---|---|---|---|
| Mean | 41.5 ± 12.3 | 43.8 ± 12.4 | 43.0 ± 12.4 |
| Age, Customized(Participants) | PBO+SOC | DZP+SOC | Total |
|---|---|---|---|
| 12 to <18 Years | 0 | 1 | 1 |
| 18 to <65 Years | 106 | 201 | 307 |
| 65 to <85 Years | 2 | 11 | 13 |
| Sex: Female, Male(Participants) | PBO+SOC | DZP+SOC | Total |
|---|---|---|---|
| Female | 101 | 198 | 299 |
| Male | 7 | 15 | 22 |
| Race/Ethnicity, Customized(Participants) | PBO+SOC | DZP+SOC | Total |
|---|---|---|---|
| American Indian/Alaska native | 9 | 20 | 29 |
| Asian | 9 | 18 | 27 |
| Black or African American | 10 | 14 | 24 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White | 63 | 130 | 193 |
| Other/Mixed | 17 | 30 | 47 |
| Race/Ethnicity, Customized(Participants) | PBO+SOC | DZP+SOC | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 78 | 118 |
| Not Hispanic or Latino | 68 | 135 | 203 |
Showing the first 100 of 177 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Aug 2020 to primary completion in May 2024, 45 months.
Results were first posted in Apr 2025, 11 months after primary completion.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 45 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapirolizumab pegol
Lupus Erythematosus, Systemic →